|1|BDNF 196A g/a and 270 c/t polymorphisms and susceptibility to Parkinson's disease: a meta-analysis. (24329127)
Lee Y.H.... Song G.G.
|2|Alcohol use disorders and risk of Parkinson's disease: findings from a Swedish national cohort study 1972-2008. (24314068)
Eriksson A.K.... Allebeck P.
|3|Diagnostic accuracy of apparent diffusion coefficient and 123I-metaiodobenzylguanidine for differentiation of multiple system atrophy and Parkinson's disease. (23613784)
Umemura A.... Sawada H.
|4|Reduced cardiac 123I-metaiodobenzylguanidine uptake in patients with spinocerebellar ataxia type 2: a comparative study with Parkinson's disease. (23929432)
De Rosa A.... Cuocolo A.
|5|Gender differences in the IL6 -174G>C and ESR2 1730G>A polymorphisms and the risk of Parkinson's disease. (22155094)
San Luciano M.... Saunders-Pullman R.
|6|Association of catechol-o-methyltransferase polymorphism (Val108/158Met) with Parkinson's disease: a meta-analysis. (23035936)
Wang Y.... Yang X.
|7|Lack of association of polymorphism in miRNA-196a2 with Parkinson's disease risk in a Chinese population. (22426473)
Haixia D.... Hang X.
|8|Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations. (21611983)
Ruiz-MartA-nez J.... MartA- MassA^ J.F.
|9|Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. (21044948)
.... Wood N.W.
|10|Differentiating Parkinson's disease from multiple system atrophy by [123I] meta-iodobenzylguanidine myocardial scintigraphy and olfactory test. (21840242)
Kikuchi A.... Takeda A.
|11|Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. (21084426)
Saad M.... Brice A.
|12|Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease. (21837367)
Gan-Or Z.... Orr-Urtreger A.
|13|Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson's disease. (20097595)
Kashihara K.... Shinya T.
|14|Myocardial 123metaiodobenzylguanidine uptake in genetic Parkinson's disease. (17975812)
Quattrone A.... Condino F.
|15|Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson's disease and essential tremor. (18067184)
Doepp F.... Schreiber S.J.
|16|Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. (18785639)
Antonini A.... Chambers M.
|17|Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis. (17219214)
GrA1newald A.... Bonifati V.
|18|Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. (17881719) |2007|
|19|DBH -1021C-->T does not modify risk or age at onset in Parkinson's disease. (17503507)
Chun L.S.... Zabetian C.P.
|20|Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. (17296539)
|21|Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies. (16818943)
Kashihara K.... Okumura Y.
|22|Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease. (15682332)
Stoffers D.... Berendse H.W.
|23|LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. (16145815)
Lesage S.... Brice A.
|24|Association studies of the adenosine A2a receptor (1976T > C) genetic polymorphism in Parkinson's disease and schizophrenia. (15719154)
Hong C.J.... Tsai S.J.
|25|123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. (15471834)
Lorberboym M.... Lampl Y.
|26|Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. (15390073)
Seppi K.... Poewe W.
|27|Sleep microstructure and neurodegeneration as measured by [123I]beta-CIT SPECT in treated patients with Parkinson's disease. (15645345)
Happe S.... Zeitlhofer J.
|28|123I-beta-CIT SPECT for imaging serotonin transporters in Parkinson's disease. (15136646)
Barthel H.... Sabri O.
|29|The DJ-1L166P mutant protein associated with early onset Parkinson's disease is unstable and forms higher-order protein complexes. (12952867)
Macedo M.G.... Rizzu P.
|30|123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. (14598060)
Antonini A.... Gerundini P.
|31|123I] meta-iodobenzylguanidine myocardial scintigraphy differentiates corticobasal degeneration from Parkinson's disease. (12583635)
Orimo S.... Takahashi A.
|32|Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease. (12732666)
Prunier C.... Baulieu J.L.
|33|123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy. (12601452)
Berding G.... Knapp W.H.
|34|Association study for Parkinson's disease and a dopamine transporter gene polymorphism (1215A/G). (12422069)
Lin C.N.... Hong C.J.
|35|No evidence of association between a dopamine transporter gene polymorphism (1215A/G) and Parkinson's disease. (11220753)
Kimura M.... Higuchi S.
|36|The -141C Ins/Del polymorphism of the dopamine D2 receptor gene is not associated with either migraine or Parkinson's disease. (11409701)
Maude S.... Clair D.S.
|37|Measuring the progression of idiopathic Parkinson's disease with [123I] beta-CIT SPECT. (11072750)
Staffen W.... Ladurner G.
|38|Phase 2 clinical study of 123I-IBF, a dopamine D2 receptor imaging agent, to evaluate clinical efficacy and safety in Parkinson's disease and Parkinson syndromes]. (10586546)
Torizuka K.... Kuwabara Y.
|39|One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. (10319746)
Booij J.... van Royen E.A.
|40|123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. (9613734)
Wenning G.K.... Poewe W.
|41|123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. (9928890)
Asenbaum S.... BrA1cke T.
|42|SPECT-evaluation of the monoamine uptake site ligand [123I](1R)-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([123I]beta-CIT) in untreated patients with suspicion of Parkinson disease. (9394097)
Eising E.G.... Coenen H.H.
|43|123I]beta-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls. (9283113)
Tissingh G.... van Royen E.A.
|44|Evaluation of benzodiazepine receptor in the cerebral cortex of Parkinson's disease using 123I-iomazenil SPECT]. (9014458)
Kawabata K.... Tachibana H.
|45|123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. (9048712)
Booij J.... van Royen E.A.
|46|Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. (9044880)
Booij J.... van Royen E.A.
|47|Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study. (8615167)
Pizzolato G.... Battistin L.
|48|Impairment of benzodiazepine receptor in Parkinson's disease evaluated by 123I-iomazenil SPECT]. (8683878)
Kawabata K.... Fukuchi M.
|49|Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study. (8748616)
Pizzolato G.... Battistin L.
|50|SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. (1838142)
Tatsch K.... Kirsch C.M.